The China MedTech Edge: September 2025 Intelligence Briefing
Delivering essential intelligence on China’s MedTech ecosystem: Policy & Compliance, Innovation, Global Strategy and beyond.
October 1, 2025
1. Regulatory & Policy Dynamics
China’s health authorities have signaled a strong focus on compliance and foundational standards this month.
1
Anti-Fraud Enforcement: The National Healthcare Security Administration (NHSA) has initiated a “100-Day Campaign” to strictly crack down on illegal activities involving medical insurance funds.
2
BCI (Brain-Computer Interface) Standardization: The NMPA has released the industry standard YY/T 1996—2025 to standardize the performance testing methods for implantable neural stimulators, with a planned implementation in 2027. This directly supports the government’s goal to establish a complete BCI standard system by 2027.
3
Recalls: The NMPA reported multiple voluntary recalls involving essential equipment, including artificial heart-lung machines, blood glucose meters, and radiotherapy software.
4
Regional Strengthening: The NMPA’s Beijing-Tianjin-Hebei (Jing-Jin-Ji) sub-center was inaugurated to strengthen regional medical device review and inspection capabilities.
2. Innovation & Technology Highlights
1
Heyu Health (和宇健康) launched its “Super Brain” AI medical service platform, integrating health big data and AI large models to enhance image analysis and diagnostic assistance capabilities.
2
Yuwell (鱼跃医疗) reinforced the IoT health ecosystem by releasing its third-generation sleep ventilator and the Anytime 5 Continuous Glucose Monitoring (CGM) system.
3
Viestar (精微视达) showcased a globally leading ultra-fine probe confocal choledochoscope (diameter < 1.0mm), a critical tool for the early diagnosis of bile duct cancer.
3. Internationalization & Overseas Expansion
Chinese MedTech companies are making significant inroads into high-value European and rapidly growing Southeast Asian markets, driven by the “Going Global” strategy.
1
SonoScape’s (开立医疗) ultrasonic bronchoscope became the first Chinese-made set to receive CE-MDR certification, and has begun European clinical studies.
2
Contec Medical Systems (康泰医学系统) obtained CE mark of its Color Doppler Ultrasound Diagnostic System.
3
Geneseeq’s（世和基因）pan-solid tumor high-throughput sequencing gene detection kit obtained FDA approval, becoming the world’s first tumor NGS large panel testing product with NMPA, FDA and CE three major approvals.
4
Yuwell established a new Indonesian subsidiary, contributing to 26.63% year-over-year business growth in the Southeast Asia region.
4. Corporate Strategy & Capital Market Glimpses
The focus remains on high-tech capabilities and global market access.
1
Robotics & Imaging: Neusoft Medical (东软医疗) and Baxter Medical (Shanghai) (百特医疗（上海）) launched the “HAN-Link Smart Platform DSA + Hybrid Operating Table” solution to improve the precision of angiography procedures.